The Beijing angle closure progression study: design and methodology.

Autor:	Liang ZQ; Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Department of Ophthalmology, Peking University People's Hospital, Eye Diseases and Optometry Institute, Beijing, China.; College of Optometry, Peking University Health Science Center, Beijing, China., Yang KY; Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Department of Ophthalmology, Peking University People's Hospital, Eye Diseases and Optometry Institute, Beijing, China.; College of Optometry, Peking University Health Science Center, Beijing, China., Lv K; Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Department of Ophthalmology, Peking University People's Hospital, Eye Diseases and Optometry Institute, Beijing, China.; College of Optometry, Peking University Health Science Center, Beijing, China., Ma Y; Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Department of Ophthalmology, Peking University People's Hospital, Eye Diseases and Optometry Institute, Beijing, China.; College of Optometry, Peking University Health Science Center, Beijing, China., Sun C; Department of Ophthalmology, Beijing Hui People's Hospital, Beijing, China., Liang G; Department of Ophthalmology, The PLA Rocket Force Characteristic Medical Center, Beijing, China., Yue YK; Department of Ophthalmology, Capital Medical University Fuxing Hospital, Beijing, China., Qin JY; Department of Ophthalmology, Peking University International Hospital, Beijing, China., Zhao Y; Department of Ophthalmology, Beijing Zhanlanlu Hospital, Beijing, China., Zhang JN; Department of Ophthalmology, Beijing Nuclear Industry Hospital, Beijing, China., Yi Q; Department of Ophthalmology, Beijing Hepingli Hospital, Beijing, China., Sun XZ; Ping An Healthcare Technology, Beijing, China., Wu HJ; Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Department of Ophthalmology, Peking University People's Hospital, Eye Diseases and Optometry Institute, Beijing, China.; College of Optometry, Peking University Health Science Center, Beijing, China.
Jazyk:	angličtina
Zdroj:	Frontiers in medicine [Front Med (Lausanne)] 2024 Jul 17; Vol. 11, pp. 1385060. Date of Electronic Publication: 2024 Jul 17 (Print Publication: 2024).
DOI:	10.3389/fmed.2024.1385060
Abstrakt:	Purpose: The purpose of this study is to summarize the design and methodology of a large-scale trial in northern China, the Beijing Angle Closure Progression Study (BAPS). This trial is designed to explore the 5-year incidence of primary angle-closure suspect (PACS) progressing to primary angle-closure (PAC) or primary angle-closure glaucoma (PACG) and to determine the possible risk factors of disease progression. Methods/design: The BAPS is a clinic-based, multicenter, noninterventional trial conducted on a sample of urban Chinese adults. Consecutive eligible patients who meet PACS diagnostic criteria will be recruited from eight participating centers, with the trial commencing on August 4, 2022. The target sample size is set at 825 subjects, with follow up planned for a minimum period of 5 years. Baseline examination will include presenting visual acuity, best corrected visual acuity, intraocular pressure (IOP), undilated slit-lamp biomicroscopy, stereoscopic evaluation of the optic disc, visual field test, optical coherence tomography evaluation of retinal nerve fiber layer, ultrasound biomicroscopy and IOLMaster. Questionnaires will also be used to collect detailed personal history. Patients are scheduled to visit the glaucoma clinic every 12 months and may visit the emergency room in case of acute attack of angle closure. Study endpoints include acute PAC episodes, elevated IOP, peripheral anterior synechiae, glaucomatous visual field defect, or glaucomatous abnormality of optic nerve. Discussion: The BAPS will provide data on the 5-year incidence of PACS progressing to PAC or PACG and determine the risk factors for disease progression. This study will also help redefine high-risk patients with PACS. Competing Interests: X-zS was employed by the company Ping An Healthcare Technology. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Liang, Yang, Lv, Ma, Sun, Liang, Yue, Qin, Zhao, Zhang, Yi, Sun and Wu.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu